Novartis/BeiGene Likely To Struggle In Crowded PD-1 Space Despite Positive First-Line Data

 
• By Alaric DeArment
  
Snails on the athletic track moves the finish line (By Sergey Lavrentev. Shutterstock 463225937)
Novartis/BeiGene face tough competition in esophageal cancer despite positive data for tislelizumab • Source: Shutterstock

More from Immuno-oncology

More from Anticancer